Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) Stock Competitors & Peer Comparison
See CELG-RI's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CELG-RI and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CELG-RI | $0.14 | +0.00% | 128.4B | N/A | N/A | +4.02% |
| LLY | $1,437.29 | +0.35% | 1.4T | 45.66 | $31.49 | +0.47% |
| JNJ | $280.41 | -0.13% | 674.8B | 26.13 | $10.73 | +1.88% |
| ABBV | $294.98 | +0.37% | 521.3B | 28.94 | $10.19 | +2.35% |
| MRK | $147.19 | -0.58% | 362.9B | 45.85 | $3.21 | +2.32% |
| NVS | $160.32 | -1.80% | 302.9B | 18.45 | $8.69 | +2.96% |
| AZN | $185.48 | -0.69% | 287.7B | 20.03 | $9.26 | +1.75% |
| AMGN | $468.11 | +0.62% | 253.2B | 20.93 | $22.37 | +2.13% |
| GILD | $169.73 | -0.67% | 210.5B | -435.21 | -$0.39 | +1.91% |
| NVO | $41.09 | +0.96% | 183.4B | 10.23 | $4.02 | +4.37% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
CELG-RI vs LLY Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, LLY has a market cap of 1.4T. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while LLY trades at $1,437.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas LLY's P/E ratio is 45.66. In terms of profitability, CELG-RI's ROE is +0.44%, compared to LLY's ROE of +0.84%. Regarding short-term risk, CELG-RI is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
CELG-RI vs JNJ Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, JNJ has a market cap of 674.8B. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while JNJ trades at $280.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas JNJ's P/E ratio is 26.13. In terms of profitability, CELG-RI's ROE is +0.44%, compared to JNJ's ROE of +0.20%. Regarding short-term risk, CELG-RI is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
CELG-RI vs ABBV Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, ABBV has a market cap of 521.3B. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while ABBV trades at $294.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas ABBV's P/E ratio is 28.94. In terms of profitability, CELG-RI's ROE is +0.44%, compared to ABBV's ROE of -2.03%. Regarding short-term risk, CELG-RI is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
CELG-RI vs MRK Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, MRK has a market cap of 362.9B. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while MRK trades at $147.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas MRK's P/E ratio is 45.85. In terms of profitability, CELG-RI's ROE is +0.44%, compared to MRK's ROE of +0.05%. Regarding short-term risk, CELG-RI is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check MRK's competition here
Novartis AG (NYSE: NVS)
CELG-RI vs NVS Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, NVS has a market cap of 302.9B. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while NVS trades at $160.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas NVS's P/E ratio is 18.45. In terms of profitability, CELG-RI's ROE is +0.44%, compared to NVS's ROE of +0.25%. Regarding short-term risk, CELG-RI is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
CELG-RI vs AZN Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, AZN has a market cap of 287.7B. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while AZN trades at $185.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas AZN's P/E ratio is 20.03. In terms of profitability, CELG-RI's ROE is +0.44%, compared to AZN's ROE of +0.22%. Regarding short-term risk, CELG-RI is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
CELG-RI vs AMGN Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, AMGN has a market cap of 253.2B. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while AMGN trades at $468.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas AMGN's P/E ratio is 20.93. In terms of profitability, CELG-RI's ROE is +0.44%, compared to AMGN's ROE of +0.86%. Regarding short-term risk, CELG-RI is more volatile compared to AMGN. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check AMGN's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
CELG-RI vs GILD Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, GILD has a market cap of 210.5B. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while GILD trades at $169.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas GILD's P/E ratio is -435.21. In terms of profitability, CELG-RI's ROE is +0.44%, compared to GILD's ROE of -0.22%. Regarding short-term risk, CELG-RI is more volatile compared to GILD. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check GILD's competition here
Novo Nordisk A/S (NYSE: NVO)
CELG-RI vs NVO Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, NVO has a market cap of 183.4B. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while NVO trades at $41.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas NVO's P/E ratio is 10.23. In terms of profitability, CELG-RI's ROE is +0.44%, compared to NVO's ROE of +0.54%. Regarding short-term risk, CELG-RI is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check NVO's competition here
Pfizer Inc. (NYSE: PFE)
CELG-RI vs PFE Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, PFE has a market cap of 167.8B. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while PFE trades at $29.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas PFE's P/E ratio is 9.65. In terms of profitability, CELG-RI's ROE is +0.44%, compared to PFE's ROE of +0.05%. Regarding short-term risk, CELG-RI is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
CELG-RI vs BMY Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, BMY has a market cap of 128.6B. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while BMY trades at $62.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas BMY's P/E ratio is 10.61. In terms of profitability, CELG-RI's ROE is +0.44%, compared to BMY's ROE of +0.44%. Regarding short-term risk, CELG-RI is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check BMY's competition here
Sanofi (NASDAQ: SNY)
CELG-RI vs SNY Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, SNY has a market cap of 116.2B. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while SNY trades at $48.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas SNY's P/E ratio is 10.55. In terms of profitability, CELG-RI's ROE is +0.44%, compared to SNY's ROE of +0.06%. Regarding short-term risk, CELG-RI is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check SNY's competition here
GSK plc (NYSE: GSK)
CELG-RI vs GSK Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, GSK has a market cap of 101.4B. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while GSK trades at $50.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas GSK's P/E ratio is 10.93. In terms of profitability, CELG-RI's ROE is +0.44%, compared to GSK's ROE of +0.23%. Regarding short-term risk, CELG-RI is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check GSK's competition here
Biogen Inc. (NASDAQ: BIIB)
CELG-RI vs BIIB Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, BIIB has a market cap of 37.5B. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while BIIB trades at $253.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas BIIB's P/E ratio is 16.00. In terms of profitability, CELG-RI's ROE is +0.44%, compared to BIIB's ROE of +0.02%. Regarding short-term risk, CELG-RI is more volatile compared to BIIB. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
CELG-RI vs HZNP Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas HZNP's P/E ratio is 61.86. In terms of profitability, CELG-RI's ROE is +0.44%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, CELG-RI is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
CELG-RI vs GRFS Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, GRFS has a market cap of 7.5B. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while GRFS trades at $8.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas GRFS's P/E ratio is 10.15. In terms of profitability, CELG-RI's ROE is +0.44%, compared to GRFS's ROE of +0.09%. Regarding short-term risk, CELG-RI is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
CELG-RI vs OGN Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while OGN trades at $13.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas OGN's P/E ratio is 4.15. In terms of profitability, CELG-RI's ROE is +0.44%, compared to OGN's ROE of +0.22%. Regarding short-term risk, CELG-RI is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
CELG-RI vs AMRN Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, AMRN has a market cap of 242.2M. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while AMRN trades at $11.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas AMRN's P/E ratio is -117.10. In terms of profitability, CELG-RI's ROE is +0.44%, compared to AMRN's ROE of -0.04%. Regarding short-term risk, CELG-RI is more volatile compared to AMRN. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check AMRN's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
CELG-RI vs MIRA Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, MIRA has a market cap of 26.1M. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while MIRA trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas MIRA's P/E ratio is -0.43. In terms of profitability, CELG-RI's ROE is +0.44%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, CELG-RI is more volatile compared to MIRA. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLX)
CELG-RI vs SCLX Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, SCLX has a market cap of 11.4M. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while SCLX trades at $1.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas SCLX's P/E ratio is -0.04. In terms of profitability, CELG-RI's ROE is +0.44%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, CELG-RI is more volatile compared to SCLX. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
CELG-RI vs SCLXW Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, SCLXW has a market cap of 8.4M. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while SCLXW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas SCLXW's P/E ratio is N/A. In terms of profitability, CELG-RI's ROE is +0.44%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, CELG-RI is more volatile compared to SCLXW. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check SCLXW's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
CELG-RI vs BDSIW Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, CELG-RI's ROE is +0.44%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, CELG-RI is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
CELG-RI vs CRXT Comparison November 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 128.4B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, CELG-RI is priced at $0.14 on the NYSE, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas CRXT's P/E ratio is -0.02. In terms of profitability, CELG-RI's ROE is +0.44%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, CELG-RI is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check CRXT's competition here